OneDigital Investment Advisors LLC Grows Stock Position in Boston Scientific Corporation $BSX

OneDigital Investment Advisors LLC grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 82.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,945 shares of the medical equipment provider’s stock after purchasing an additional 8,544 shares during the period. OneDigital Investment Advisors LLC’s holdings in Boston Scientific were worth $1,850,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in BSX. Gerber Kawasaki Wealth & Investment Management increased its stake in Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after buying an additional 99 shares during the period. Crown Wealth Group LLC increased its position in shares of Boston Scientific by 4.7% during the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after acquiring an additional 100 shares during the last quarter. Sound View Wealth Advisors Group LLC lifted its stake in shares of Boston Scientific by 3.9% in the second quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock worth $294,000 after acquiring an additional 103 shares in the last quarter. Scotia Capital Inc. boosted its holdings in Boston Scientific by 0.7% in the second quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider’s stock valued at $1,621,000 after purchasing an additional 104 shares during the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors grew its stake in Boston Scientific by 2.3% during the 3rd quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 4,776 shares of the medical equipment provider’s stock valued at $466,000 after purchasing an additional 108 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $75.27 on Wednesday. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The firm’s 50-day moving average price is $88.52 and its two-hundred day moving average price is $96.13. Boston Scientific Corporation has a 52-week low of $72.69 and a 52-week high of $109.50. The stock has a market capitalization of $111.70 billion, a P/E ratio of 38.80, a P/E/G ratio of 1.03 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period last year, the company earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on BSX shares. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Canaccord Genuity Group cut their price target on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a report on Monday, February 2nd. Morgan Stanley dropped their target price on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Finally, Weiss Ratings lowered shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $108.36.

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.